Pierre Nicolas
6 Papers
3 Citations
Pierre Nicolas is an academic researcher. The author has contributed to research in topics: Palonosetron & Ondansetron. The author has an hindex of 2, co-authored 4 publications.
Chat about Author
Papers
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Gabor G. Kovacs,A. Wachtel,E. Basharova,T. Spinelli,Pierre Nicolas,Edita Kabickova +5 more
21
Palonosetron vs ondansetron: Prevention of chemotherapy-induced nausea and vomiting in pediatric patients in a multicycle study.
Edita Kabickova,Antonio Wachtel,Elena Basharova,Tulla Spinelli,Pierre Nicolas,Gabor G. Kovacs +5 more
TL;DR: The CR rate was highest in the PALO 20 µg/kg group in all phases of cycles 1, 3 and 4 with statistical non-inferiority shown for this dose vs OND in the acute phase of cycle 1 (see table).
2
Oral versus intravenous palonosetron in Chinese cancer patients receiving moderately emetogenic chemotherapy: A non-inferiority phase III trial.
TL;DR: Non-inferiority of oral versus IV PALO in the acute phase was demonstrated in Chinese patients, and the two formulations showed similar efficacy/safety.
1
Optimizing the treatment sequence: the cumulative clinical benefit of treatment initiation with deucravacitinib versus apremilast over 52 weeks in patients with moderate to severe plaque psoriasis from the POETYK PSO-1 trial
April W. Armstrong,Sang Hee Park,Viktor V. Chirikov,Pierre Nicolas,Wei Jhih Wang,Matthew J. Colombo,Vardhaman Patel +6 more
TL;DR: In this article , the authors proposed a method to solve the problem of "N/A/A" and "A/B/C/D/C" in the problem.
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study
Gabor G. Kovacs,Antonio Wachtel,Elena Basharova,Tulla Spinelli,Pierre Nicolas,Edita Kabickova +5 more
TL;DR: The primary efficacy objective was to show the non-inferiority of palonosetron versus ondansetron during the acute phase of the first on-study chemotherapy cycle, as assessed in the population of randomly assigned patients who received moderately or highly emetogenic chemotherapy and an active study drug.